Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2CNS 1

Conditions

Stomach Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Colorectal Neoplasms 1Adenocarcinoma of the Stomach 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
GC1118 × Clear all
NCT03618667 2023-05-12

GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

Samsung Medical Center

Phase 2 Completed
13 enrolled
CNS

Glioblastoma

NCT04077255 2022-11-30

EGFR-targeted Therapy for Gastric Cancer

National Cancer Center, Korea

Phase 2 Unknown
19 enrolled
Gastrointestinal

Adenocarcinoma of the Stomach

NCT02352571 2016-07-06

Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer

GC Biopharma Corp

Phase 1 Unknown
72 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡